{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:19:46Z","timestamp":1764937186234},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,12,1]]},"DOI":"10.2169\/internalmedicine.5216-20","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T22:07:52Z","timestamp":1595887672000},"page":"3055-3059","source":"Crossref","is-referenced-by-count":14,"title":["Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab"],"prefix":"10.2169","volume":"59","author":[{"given":"Koki","family":"Nakashima","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan"},{"name":"Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Demura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Oi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mio","family":"Tabata","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Shiozaki","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Akai","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamotsu","family":"Ishizuka","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 359: 1350-1355, 2018.","DOI":"10.1126\/science.aar4060"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8: 1069-1086, 2018.","DOI":"10.1158\/2159-8290.CD-18-0367"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Antonia SJ, Villegas A, Daniel D, et al. Durvalmab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377: 1919-1929, 2017.","DOI":"10.1056\/NEJMoa1709937"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with Durvalmab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379: 2342-2350, 2018.","DOI":"10.1056\/NEJMoa1809697"},{"key":"5","unstructured":"5. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36: 1714-1768, 2018."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Reynolds K, Thomas M, Dougan M. Diagnosis and management of hepatitis in patients on checkpoint blockade. Oncologist 23: 991-997, 2018.","DOI":"10.1634\/theoncologist.2018-0174"},{"key":"7","unstructured":"7. Cheung V, Gupta T, Payne M, et al. Immunotherapy-related hepatitis: real-world experience from a tertiary centre. Frontline Gastroenterol 10: 364-371, 2019."},{"key":"8","unstructured":"8. Corrigan M, Haydon G, Thompson F, et al. Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: a case report. JHEP Rep 1: 66-69, 2019."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Shivaji UN, Jeffery L, Gui X, et al. Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. Ther Adv Gastroenterol 12: 1-15, 2019.","DOI":"10.1177\/1756284819884196"},{"key":"10","unstructured":"10. Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54: 139-148, 2016."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kleiner D, Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci 57: 2233-2240, 2012.","DOI":"10.1007\/s10620-012-2140-5"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Sue M, Ueno M, Takabata H, et al. A case report of pembrolizumab-induced liver injury: the implication of CD8-positive lymphocytes in the immune-related adverse event. Kanzo 59: 571-577, 2018 (in Japanese, Abstract in English).","DOI":"10.2957\/kanzo.59.571"},{"key":"13","unstructured":"13. Zen Y, Yeh MM. Checkpoint inhibitor-induced liver injury: a novel form of liver disease emerging in the era of cancer immunotherapy. Semin Diagn Pathol 36: 434-440, 2019."},{"key":"14","unstructured":"14. Mathew TV, Bindal P, Ann AS, et al. Nivolmab-induced hepatitis: a rare side effect of an immune check point inhibitor. J Oncol Pharm Pract 26: 459-461, 2020."},{"key":"15","unstructured":"15. Imoto K, Kohjima M, Hioki T, et al. Clinical features of liver injury induced by immune checkpoint inhibitors in Japanese patiets. Can J Gastroenterol Hepatol. Forthcoming."},{"key":"16","unstructured":"16. Coutzac C, Adam J, Soularue E, et al. Colon immune-related adverse events: anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathological entitis. J Crohns Colitis 11: 1238-1246, 2017."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Perez-Ruiz E, Minute L, Otano I, et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature 569: 428-432, 2019.","DOI":"10.1038\/s41586-019-1162-y"},{"key":"18","doi-asserted-by":"crossref","first-page":"1722023","DOI":"10.1080\/2162402X.2020.1722023","volume":"9","author":"KH Kim","year":"2020","unstructured":"18. Kim KH, Hur JY, Cho J, et al. Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. Oncoimmunology 9: 1722023, 2020.","journal-title":"OncoImmunology","ISSN":"http:\/\/id.crossref.org\/issn\/2162-4011","issn-type":"print"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Mizuno K, Ito T, Ishigami M, et al. Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies. J Gastroenterol 55: 653-661, 2020.","DOI":"10.1007\/s00535-020-01677-9"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kawakami H, Tanizaki J, Tanaka K, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs 35: 529-536, 2017.","DOI":"10.1007\/s10637-017-0453-0"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/23\/59_5216-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T04:48:04Z","timestamp":1607143684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/23\/59_5216-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":20,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5216-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,1]]}}}